Literature DB >> 4019510

Studies of synthetic peptide analogs of the amphipathic helix. Structure of complexes with dimyristoyl phosphatidylcholine.

G M Anantharamaiah, J L Jones, C G Brouillette, C F Schmidt, B H Chung, T A Hughes, A S Bhown, J P Segrest.   

Abstract

The amphipathic helix hypothesis for the lipid-associating domains of exchangeable plasma apolipoproteins has been further studied by analysis of the structure of the complexes formed between four synthetic peptide analogs of the amphipathic helix and dimyristoyl phosphatidylcholine (DMPC). Density gradient ultracentrifugation, negative stain electron microscopy, nondenaturing gradient gel electrophoresis, 1H NMR, high sensitivity differential scanning calorimetry, and circular dichroism were the techniques used in these studies. The two analogs Asp-Trp-Leu-Lys-Ala-Phe-Tyr-Asp-Lys-Val-Ala-Glu-Lys-Leu-Lys-Glu-Ala-Phe (18A) and 18A-Pro-18A whose sequences most strongly mimic native amphipathic sequences were found also most strongly to mimic apolipoprotein A-I in DMPC complex structure. The covalently linked dimer of the prototype amphipathic analog 18A, 18A-Pro-18A, appears to have greater lipid affinity than 18A. This presumably is the result of the cooperativity provided by two covalently linked lipid-associating domains in 18A-Pro-18A. The studies further suggest that the charge-reversed analog of the prototype 18A, reverse-18A, has the lowest lipid affinity of the four analogs studied and forms only marginally stable discoidal DMPC complexes. We postulate that this low lipid affinity is due predominantly, but not necessarily exclusively, to the lack of a hydrophobic contribution of lysine residues at the polar-nonpolar interface of reverse-18A versus 18A. The intermediate lipid affinity of des-Val10-18A, the fourth analog peptide, to produce a rank order of 18A-Pro-18A greater than 18A greater than des-Val10-18A greater than reverse-18A, supports this interpretation. Des-Val10-18A which has Val deleted from 18A has an amphipathic helical structure partially disrupted by the shift of 2 lysine residues away from the polar-nonpolar interface.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4019510

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  81 in total

1.  A novel apolipoprotein C-II mimetic peptide that activates lipoprotein lipase and decreases serum triglycerides in apolipoprotein E-knockout mice.

Authors:  Marcelo J A Amar; Toshihiro Sakurai; Akiko Sakurai-Ikuta; Denis Sviridov; Lita Freeman; Lusana Ahsan; Alan T Remaley
Journal:  J Pharmacol Exp Ther       Date:  2014-11-13       Impact factor: 4.030

Review 2.  Nanodiscs versus macrodiscs for NMR of membrane proteins.

Authors:  Sang Ho Park; Sabrina Berkamp; Gabriel A Cook; Michelle K Chan; Hector Viadiu; Stanley J Opella
Journal:  Biochemistry       Date:  2011-09-30       Impact factor: 3.162

Review 3.  Low high-density lipoprotein cholesterol: physiological background, clinical importance and drug treatment.

Authors:  Martin Hersberger; Arnold von Eckardstein
Journal:  Drugs       Date:  2003       Impact factor: 9.546

4.  Oral administration of L-mR18L, a single domain cationic amphipathic helical peptide, inhibits lesion formation in ApoE null mice.

Authors:  Shaila P Handattu; Geeta Datta; Richard M Epand; Raquel F Epand; Mayakonda N Palgunachari; Vinod K Mishra; Candyce E Monroe; Tamara D Keenum; Manjula Chaddha; G M Anantharamaiah; David W Garber
Journal:  J Lipid Res       Date:  2010-09-14       Impact factor: 5.922

5.  Apolipoprotein mimetic peptides: Mechanisms of action as anti-atherogenic agents.

Authors:  David O Osei-Hwedieh; Marcelo Amar; Dmitri Sviridov; Alan T Remaley
Journal:  Pharmacol Ther       Date:  2010-12-21       Impact factor: 12.310

6.  Apolipoprotein E mimetic is more effective than apolipoprotein A-I mimetic in reducing lesion formation in older female apo E null mice.

Authors:  Gaurav Nayyar; David W Garber; Mayakonda N Palgunachari; Candyce E Monroe; Tamara D Keenum; Shaila P Handattu; Vinod K Mishra; G M Anantharamaiah
Journal:  Atherosclerosis       Date:  2012-06-23       Impact factor: 5.162

7.  Apolipoprotein A-I variants. Naturally occurring substitutions of proline residues affect plasma concentration of apolipoprotein A-I.

Authors:  A von Eckardstein; H Funke; A Henke; K Altland; A Benninghoven; G Assmann
Journal:  J Clin Invest       Date:  1989-12       Impact factor: 14.808

Review 8.  Multiple indications for anti-inflammatory apolipoprotein mimetic peptides.

Authors:  Brian J Van Lenten; Mohamad Navab; G M Anantharamaiah; Georgette M Buga; Srinivasa T Reddy; Alan M Fogelman
Journal:  Curr Opin Investig Drugs       Date:  2008-11

9.  Membrane interaction of a beta-structure-forming synthetic peptide comprising the 116-139th sequence region of the cytotoxic protein alpha-sarcin.

Authors:  J M Mancheño; M Gasset; J P Albar; J Lacadena; A Martínez del Pozo; M Oñaderra; J G Gavilanes
Journal:  Biophys J       Date:  1995-06       Impact factor: 4.033

10.  Orientational behavior of phosphatidylcholine bilayers in the presence of aromatic amphiphiles and a magnetic field.

Authors:  C R Sanders; J E Schaff; J H Prestegard
Journal:  Biophys J       Date:  1993-04       Impact factor: 4.033

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.